Although relatively rare, thymomas can be involved in a considerable variety of clinical presentations. Clinicians should be mindful of the breadth of associations with other diseases, including autoimmune disorders and many secondary nonthymic malignancies. For the pathologist, knowledge of the extremely varied histopathologic presentation of thymoma is vital to formulate a proper differential, workup, and diagnosis. The presented case illustrates the finding of very rare metastatic thymoma involvement of bone marrow, identified during evaluation for pancytopenia. The history of prior prostate cancer and an uncharacterized pancreatic lesion, as well as the familial presentation, also suggests a possible underlying hereditary syndrome.
T umors of the thymus gland (thymomas) are rare. Thymomas have a strong clinical association with autoimmune disorders, including myasthenia gravis, polymyositis, systemic lupus erythematosus, myocarditis, pure red cell aplasia, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and Graves disease, with a varying frequency of presentation. It is extremely rare for thymomas to metastasize to the bone marrow. We report a case of metastatic thymoma discovered on a bone marrow biopsy submitted for evaluation of pancytopenia.
CASE REPORT
A 77-year-old man with a history of prostate cancer presented with an acute onset of back pain and was found to have a circumferential epidural tumor at T12, with signifi cant cord compression and edema. Following spinal radiation, he received six cycles of paclitaxel and carboplatin chemotherapy for presumed metastatic carcinoma. A follow-up computed tomography (CT) scan showed an enlarging mediastinal mass as well as a solitary low-density liver lesion. CT-guided core biopsy of the mediastinal mass showed a carcinoma that was positive for squamous markers p63 and high-molecular-weight keratin; a minor component of lymphocytes was predominantly CD4 + / CD8 + T cells. Although a thymic neoplasm was considered, pulmonary non-small cell carcinoma was favored. Tests for ALK gene rearrangement by fl uorescent in situ hybridization and EGFR mutation by polymerase chain reaction were both negative. Subsequent imaging showed increasing disease activity in the chest and a 0.5 cm liver lesion, with no bone disease. Single-agent docetaxel was started but discontinued 6 months later due to neuropathy. On follow-up, the liver lesion was enlarging, and a new pancreatic tail lesion was identifi ed with a radiologic impression of a low-grade neuroendocrine tumor. Liver biopsy showed a lesion with a prominent component of thymic-type, CD1a-positive lymphocytes and epithelial cells consistent with thymoma, World Health Organization (WHO) type B2. Chemotherapy for relapsing thymoma, including cisplatin, doxorubicin, and cyclophosphamide, was started; pancytopenia refractory to erythropoietin with normal iron studies prompted a posterior iliac crest marrow biopsy.
Th e trephine biopsy showed extensive involvement by predominantly small lymphocytes, with scattered, cytologically bland epithelial cells and broad bands of connective tissue forming lobules (Figure 1a) . Immunohistochemistry testing showed a background of cells positive for cytokeratin (Figure 1b) , with the lymphoid cells predominantly positive for CD3 and CD1a (Figure 1c) . Among other stains, CD20 showed rare B cells, CD34 highlighted less than 1% positive cells, EMA was dim and patchy, PAX8 was negative, and CD71 showed virtually absent erythroid precursors; prostate-specifi c antigen immunostains were negative. Th e hematopoietic cells in the marrow biopsy, although displaced by the thymoma, showed no signifi cant dyspoietic changes. Iron stores as assessed by Prussian blue stain were adequate. Chromosomal analysis demonstrated a normal karyotype, and fl ow cytometry found no evidence of lymphoproliferative disease.
Th ese fi ndings are consistent with metastatic thymoma involving the bone marrow. Treatment with the kinase inhibitor sunitinib was started. Interestingly, it was discovered that one of the patient's immediate family members also had metastatic thymoma.
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DISCUSSION
Th ymoma refers to neoplasms of thymic epithelial cells, usually in the anterior mediastinum (1). Th ese lesions are rare, with an incidence of 0.13 per 100,000 person-years. An agerelated rise in incidence in middle age is seen, peaking in the seventh decade (2) . Clinical presentation is most often myasthenia gravis, followed by compression of mediastinal tissues (3); systemic symptoms such as fever, malaise, or weight loss may occur. Radiologic appearance varies, with benign lesions appearing more regular and malignant thymomas appearing more irregular and uneven.
Th e clinical association with autoimmune disorders should be emphasized: 40% of thymoma patients have a (presumably paraneoplastic) autoimmune condition, most commonly myasthenia gravis (4). Other associated entities include polymyositis, systemic lupus erythematosus, peripheral neuropathy, myocarditis, graft-versus-host-disease-like symptoms, hypogammaglobulinemia, pure red blood cell aplasia, aplastic anemia, rheumatoid arthritis, scleroderma, Sjögren syndrome, and Graves disease. Such strong autoimmune correlations merit consideration of thymoma as a component of a syndrome (5) . Due to the rarity of thymomas, identifi cation of a distinct genetic link has proven diffi cult; however, epidemiological clustering of thymomas and neuroendocrine tumors is observed in relation to multiple endocrine neoplasia syndrome (6) , which is associated with pituitary adenomas, parathyroid hyperplasia, and pancreatic neuroendocrine tumors.
Th e gross appearance of a thymoma is often a solid yellow mass with a lobular confi guration accentuated by prominent fi brous trabeculae (3), with variable necrosis, hemorrhage, or cystic spaces or degeneration, features of which do not portend a poor prognosis (7) . Circumscription and encapsulation correspond to less aggressive lesions. Care should be taken to distinguish cystic thymomas from reactive multilocular thymic cysts (8) . Th e histologic classifi cation of thymomas has undergone frequent revision. Th e most recent WHO classifi cation defi nes categories based on histology of the neoplastic epithelial cells: uniformly bland, spindled, or oval-shaped (type A); round or polygonal (type B1, B2, or B3); or both (type AB) (1) .
Type A thymomas, also known as "spindle cell" or "medullary" thymomas, represent a small portion of thymomas, less associated with myasthenia gravis, with a bland spindled pattern and rare immature cortical-type CD4 + /CD8 + lymphocytes. Type AB, characterized by components of both lymphocytepoor type A and lymphocyte-rich type B histology, shows predominantly small, polygonal epithelial cells, with round, oval, or spindled nuclei and inconspicuous nucleoli. Type A and AB thymomas have a favorable prognosis; most can be treated surgically.
Type B1, or lymphocyte-rich, thymomas closely resemble the histology of normal thymus, with cortical areas of immature lymphocytes, many scattered foci of medullary differentiation, and scant neoplastic epithelial cells, typically with a well-defi ned capsule. Th ese are often found during workup of myasthenia gravis, and although slightly more aggressive than A or AB, type B1 thymomas tend toward a favorable prognosis. Type B2, or cortical, thymomas are very strongly correlated with myasthenia gravis (30%-82%). Histology shows a lobular architecture with a more prominent epithelial component and less lymphocytic infi ltrate compared to the B1 type. Th e T cells show an immature cortical phenotype, with mature T cells in rare medullary islands.
Type B3, or well-diff erentiated, thymomas are also strongly correlated with myasthenia gravis, with frequent local compressive symptoms and local invasion. Th ese often present at higher stages, resulting in poorer overall survival. Histology shows few lymphocytes, with sheets of tumor cells in lobules separated by thick hyalinized septae.
In cases with overt cytological atypia, the tumor is classifi ed as a thymic carcinoma, or "type C thymoma." Many variants exist, but they lack autoimmune associations and the immature T-cell phenotype; Epstein-Barr virus may play an etiologic role in poorly diff erentiated squamous or undiff erentiated thymic carcinomas. Notably, thymomas can contain any combination of histologic subtypes; adequate sampling is vital to ensure proper characterization of the tumor. Staging is integral to prognosis and treatment and depends primarily on capsular invasion, either microscopic or macroscopic, or local invasion if no distinct capsule is present. Curiously, the histologic subtype of thymic tumors, independent from stage, correlates less well with survival (9) . A favorable prognosis for thymic neoplasms is associated with fi ve discrete factors: the presence of myasthenia gravis, younger age, completeness of resection, low stage, and tumor type A or B (10). Treatment of stage I and II tumors depends on complete surgical resection, with most deaths due to other causes (11) . Advanced disease, often exhibiting pericardial or pleural implants, can benefi t from postexcisional radiotherapy (12) . Th e preferred chemotherapy for metastatic lesions is cisplatin with vincristine, doxorubicin, and etoposide (13) . Distant metastases are rare and have been reported in lymph nodes, lung, liver, ovary (type B1) (14) , and breast (type AB) (15) . Bone involvement is reported, but often as direct invasion into adjacent ribs and vertebrae (16) . True thymoma metastases to the bone marrow are extremely unusual, with only rare cases reported in the literature (17) .
